Insys' Sublingual Buprenorphine Spray Fails At US FDA Panel, But Some Members See Future In Limited Role
Main concerns involved the delayed onset to meaningful pain relief and the safety signal of hypoxia.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
US FDA advisory committee will hear agency's concerns with Buvaya's effectiveness, safety, and abuse potential.